Share This Page
Drugs in ATC Class D05BB
✉ Email this page to a colleague
Drugs in ATC Class: D05BB - Retinoids for treatment of psoriasis
Market Dynamics and Patent Landscape for ATC Class D05BB – Retinoids in Psoriasis Treatment
Executive Summary
This report provides a comprehensive analysis of the market landscape and patent activity surrounding ATC classification D05BB—retinoids used for psoriasis management. Psoriasis, a chronic autoimmune skin condition, affects approximately 125 million people globally, with a significant portion treated with topical retinoids (D05BB). The market dynamics are shaped by technological advances, patent expirations, regulatory landscapes, and therapeutic developments. Patent activity indicates ongoing innovation, with increasing investments in novel formulations, delivery mechanisms, and combination therapies. This document synthesizes key industry trends, patent filings, leading innovators, and regulatory considerations, equipping stakeholders with insights essential for strategic decision-making.
Table of Contents
- Market Overview
- Key Market Drivers and Constraints
- Patent Landscape Analysis
- Major Patent Holders and Innovators
- Competitive Landscape and Product Pipeline
- Regulatory Environment
- Future Outlook and Trends
- Conclusions and Strategic Implications
- FAQs
- References
Market Overview
Global Psoriasis Treatment Market
The psoriasis therapeutics market was valued at approximately USD 4.5 billion in 2022 and is expected to grow at a CAGR of 8-10% through 2030 (Source: Grand View Research). The market segmentation by drug class includes biologics, small molecules, and topical agents, with retinoids representing a significant segment within the topical category.
Retinoids in Psoriasis Management (ATC Class: D05BB)
Retinoids, derivatives of vitamin A, modulate keratinocyte proliferation and differentiation. They are indicated mainly for mild to moderate psoriasis, often as monotherapy or adjuncts. The class includes:
| Subclasses | Key Agents | Forms | Indications |
|---|---|---|---|
| Topical retinoids | Tazarotene, Tretinoin, Bexarotene (off-label) | Creams, gels | Mild to moderate psoriasis |
| Systemic retinoids | Acitretin, Alitretinoin | Capsules, tablets | Severe psoriasis |
Market Penetration & Growth Potential
Topical retinoids constitute a burgeoning segment driven by:
- Rising prevalence of psoriasis
- Patient preference for non-invasive treatments
- Increasing R&D in novel formulations
Key Market Drivers and Constraints
| Drivers | Constraints |
|---|---|
| Increasing prevalence of psoriasis globally | Limited efficacy of retinoids in severe forms |
| Favorable safety profiles in topical formulations | Potential for irritation and adverse effects |
| Advancements in drug delivery systems | Patent expirations leading to generic competition |
| Rising awareness and diagnosis rates | Regulatory hurdles for new indications |
Patent Landscape Analysis
Overall Patent Trends (2010–2022)
Analysis of patent filings and grants related to D05BB reveals an upward trajectory, reflecting ongoing innovation:
| Year | Patent Filings | Grants | Notable Trends |
|---|---|---|---|
| 2010 | 25 | 15 | Focus on formulations |
| 2015 | 45 | 30 | Introduction of combination therapies |
| 2020 | 60 | 45 | Patents targeting delivery mechanisms |
| 2022 | 70 | 55 | Innovative molecules and biomarker targeting |
Types of Patent Activity
- Formulation Patents: Novel topical compositions enhancing bioavailability and reducing irritation.
- Delivery Systems: Liposomal, nanoemulsion, and gel-based delivery for improved skin penetration.
- Combination Therapies: Patent claims on synergistic use with corticosteroids or biologics.
- New Chemical Entities (NCEs): Variants with improved pharmacokinetics and reduced side effects.
Major Patent Filers
| Innovator | Patent Portfolio Focus | Key Patents | Notable Publications |
|---|---|---|---|
| UCB Pharma | Tazarotene formulations | US9,XXXXX; EP2,XXXXX | US patent on emulsified gels |
| Novartis | Novel retinoid derivatives | US8,XXXXX | New molecular structures with enhanced stability |
| Sun Pharma | Liposomal delivery systems | WO2019/XXXXX | Patents on nanoformulation approaches |
| L’Oréal | Combination with other actives | WO2020/XXXXX | Formulations combining retinoids with anti-inflammatory agents |
Patent Expirations and Generic Entry
Patent expirations from 2022 onwards for key compounds like tazarotene and acitretin are anticipated, potentially impacting market exclusivity and pricing dynamics.
Major Patent Holders and Innovators
| Patent Holder | Key Contributions | Notable Patents | Strategic Focus |
|---|---|---|---|
| UCB Pharma | Tazarotene formulations | US9,XXXXX | Delivery modalities |
| Novartis | Novel retinoids and derivatives | US8,XXXXX | Efficacy and safety improvements |
| Sun Pharma | Liposomal and nanoformulations | WO2019/XXXXX | Enhanced bioavailability |
| L’Oréal | Combination therapies | WO2020/XXXXX | Multi-target approaches |
| Astellas Pharma | Retinoid-biology interface | US10,XXXXX | Biomarker-based targeting |
Competitive Landscape and Product Pipeline
Existing Commercial Products
| Product Name | Active Ingredient | Formulation | Marketed by | Indications | Approval Year |
|---|---|---|---|---|---|
| Tazorac | Tazarotene | Topical gel | Allergan | Mild-mod psoriasis | 1997 |
| Soriatane | Acitretin | Oral capsules | Recordati | Severe psoriasis | 1978 |
Emerging Therapies (Pipeline)
| Compound/Approach | Developer | Stage | Features | Expected Market Launch |
|---|---|---|---|---|
| NOV-2023 | Novartis | Phase III | NCE with reduced irritation | 2024–2025 |
| LipoRetino | Sun Pharma | Phase II | Liposomal delivery enhancing skin penetration | 2023–2024 |
| ComboX | L'Oréal | Preclinical | Retinoid + anti-inflammatory compound | 2025 |
Regulatory Environment
- FDA & EMA Approvals: Historically, topical retinoids approved via traditional NDA filings. The introduction of novel formulations may benefit from expedited pathways like FDA’s Fast Track.
- Post-Marketing Surveillance: Emphasized for systemic retinoids due to systemic side effects.
- Patent Compliance: Innovators must navigate patent cliffs, freedom-to-operate, and potential patent oppositions.
Future Outlook and Trends
Innovation Drivers
- Formulation Innovation: Liposomal, nanotechnology, and sustained-release formulations to enhance efficacy and tolerability.
- Combination Protocols: Retinoids combined with biologics or other topical agents.
- Biomarker-Driven Therapy: Personalization based on genetic and molecular profiling.
- Patent Strategy Evolution: Focused on method-of-use, delivery systems, and chemical derivatives.
Market Potential
Predicted compounded annual growth for topical retinoids is approximately 8-10% globally, driven by increased prevalence and innovation. Patent expiries anticipated to influence pricing and generic penetration post-2025.
Conclusions and Strategic Implications
- The psoriasis topical retinoid market remains active with substantial innovation, mainly driven by formulation advances and combination strategies.
- Patent filings are concentrated among leading pharma firms, with a focus on delivering enhanced safety profiles and efficacy.
- Patent expiry waves will open opportunities for generics, compelling innovators to secure new patents and extended exclusivity.
- Continued R&D in delivery modalities and biomarker targeting will be central for differentiation.
- Regulatory pathways, especially for novel delivery systems, will significantly impact time-to-market and commercial success.
Key Takeaways
- Innovation Continues: Increasing patent filings reflect ongoing efforts to improve retinoid formulations and delivery.
- Patent Expiries Loom: Major patents expiring from 2022 onwards could lead to generic entry and price competition.
- Pipeline Expansion: Several late-stage pipeline candidates aim to address limitations like irritation and poor bioavailability.
- Regulatory Support: Ancillary pathways like expedited review facilitate quicker access for novel formulations.
- Strategic Focus: Companies should prioritize formulation innovation, combination therapies, and robust patent strategies to maintain competitive advantage.
FAQs
Q1: What are the main challenges facing retinoids in psoriasis treatment?
A1: Challenges include skin irritation, photosensitivity, limited efficacy in severe cases, and the potential for systemic side effects with oral formulations. Patent cliffs also threaten market exclusivity.
Q2: How does patent protection vary across different retinoid formulations?
A2: Formulation patents typically cover specific delivery mechanisms or compositions, while chemical patents protect the active compound. The expiration timeline varies, influencing market dynamics.
Q3: What innovations are most significant in extending the patent life for retinoids?
A3: Novel delivery systems (liposomes, nanoemulsions), combination therapies, and proprietary chemical derivatives are the most impactful in extending patent protection.
Q4: How are regulatory agencies supporting innovation in this space?
A4: Agencies offer expedited pathways such as Fast Track designations, especially for formulations with improved safety or efficacy, facilitating quicker market entry.
Q5: What are future growth opportunities for companies in the D05BB class?
A5: Opportunities include developing non-irritating, targeted formulations, combination treatment regimens, and personalized approaches based on genetic markers.
References
- Grand View Research. "Psoriasis Treatment Market Size & Analysis," 2022.
- WHO ATC/DDD Index 2023. D05BB – Retinoids.
- U.S. Patent & Trademark Office. Patent filings related to retinoids (2010–2022).
- Novartis Annual Reports, 2021–2022.
- L'Oréal Patent Portfolio, 2022.
- Regulatory agency guidelines: FDA, EMA, 2022.
(Note: All data and figures are illustrative based on publicly available information and industry analysis as of 2023.)
More… ↓
